Topic Hub
3 clinically reviewed articles, written and peer-reviewed by the HealthRX Medical Team.
Explore
Showing 3 of 3 clinical reviews.
Alirocumab (Praluent) reduces apolipoprotein B (ApoB) by 36 to 54% in clinical trials. Learn the mechanism, timeline, key trial data from ODYSSEY OUTCOMES, and when to monitor ApoB on Praluent.
Read clinical reviewAlirocumab (Praluent) has minimal effect on AST in most patients. Learn what clinical trials show about Praluent and liver enzymes, when to monitor AST, and what elevations mean.
Read clinical reviewAlirocumab (Praluent) lowers Lp(a) by roughly 20-30%. Learn the clinical evidence from ODYSSEY OUTCOMES, the PCSK9-mediated mechanism, expected time course, and when to check Lp(a) levels on therapy.
Read clinical review